


A-770041

Cat. No.:	HY-11011		
CAS No.:	869748-10-7		
Molecular Formula:	C ₃₄ H ₃₉ N ₉ O ₃		
Molecular Weight:	621.73		
Target:	Src		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (160.84 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.6084 mL	8.0421 mL	16.0842 mL
	5 mM	0.3217 mL	1.6084 mL	3.2168 mL
	10 mM	0.1608 mL	0.8042 mL	1.6084 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling. IC50 value: 147 nM Target: Lck

REFERENCES

[1]. Stachlewitz RF, et al. A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. *J Pharmacol Exp Ther.* 2005 Oct;315(1):36-41.

[2]. Andrew Burchat, et al. Discovery of A-770041, a src-family selective orally active Lck inhibitor that prevents organ allograft rejection *Bioorganic & Medicinal Chemistry Letters* Volume 16, Issue 1, 1 January 2006, Pages 118-122

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA